关键信息
-
基因名
SLC18A3
- 应用
-
别名
AChR; MGC12716; rVAT; Slc18a3; Solute carrier family 18 (vesicular acetylcholine) member 3; Solute carrier family 18 (vesicular monoamine) member 3; Solute carrier family 18 member 3; VAChT; VACHT_HUMAN; Vesicular acetylcholine transporter
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q16572
-
氨基酸序列
MESAEPAGQARAAATKLSEAVGAALQEPRRQRRLVLVIVCVALLLDNMLYMVIVPIVPDYIAHMRGGGEGPTRTPEVWEPTLPLPTPANASAYTANTSASPTAAWPAGSALRPRYPTESEDVKIGVLFASKAILQLLVNPLSGPFIDRMSYDVPLLIGLGVMFASTVLFAFAEDYATLFAARSLQGLGSAFADTSGIAMIADKYPEEPERSRALGVALAFISFGSLVAPPFGGILYEFAGKRVPFLVLAAVSLFDALLLLAVAKPFSAAARARANLPVGTPIHRLMLDPYIAVVAGALTTCNIPLAFLEPTIATWMKHTMAASEWEMGMAWLPAFVPHVLGVYLTVRLAARYPHLQWLYGALGLAVIGASSCIVPACRSFAPLVVSLCGLCFGIALVDTALLPTLAFLVDVRHVSVYGSVYAIADISYSVAYALGPIVAGHIVHSLGFEQLSLGMGLANLLYAPVLLLLRNVGLLTRSRSERDVLLDEPPQGLYDAVRLRERPVSGQDGEPRSPPGPFDECEDDYNYYYTRS
-
分子量
58.6 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
SLC18A3, also known as the vesicular monoamine transporter 2 (VMAT2), plays a crucial role in neurotransmitter storage and release within presynaptic vesicles. This protein is responsible for the uptake of monoamines such as dopamine, serotonin, and norepinephrine, thereby contributing to various physiological processes including mood regulation, motor control, and reward pathways. Dysregulation of SLC18A3 has been implicated in several neurological disorders, including Parkinson's disease, schizophrenia, and depression, making it a significant target for therapeutic intervention. Recent studies have highlighted the potential of recombinant SLC18A3 proteins in drug discovery, allowing for a better understanding of its structure-function relationship, interactions with ligands, and its modulation by pharmacological agents. By expressing and purifying the recombinant SLC18A3 protein, researchers aim to facilitate high-throughput screenings for compounds that can selectively enhance or inhibit its activity, providing insights into how alterations in monoamine transmission might affect neurological health. The use of recombinant techniques also allows for the exploration of post-translational modifications and their impact on transporter function, paving the way for novel approaches in the development of targeted therapies for mental health disorders. Understanding the mechanistic details of SLC18A3 could unveil new pathways for intervention and potentially lead to innovative treatment options that leverage the modulation of monoamine vesicular transport in the brain.
